BR112017028318A2 - antibacterial compounds - Google Patents

antibacterial compounds

Info

Publication number
BR112017028318A2
BR112017028318A2 BR112017028318A BR112017028318A BR112017028318A2 BR 112017028318 A2 BR112017028318 A2 BR 112017028318A2 BR 112017028318 A BR112017028318 A BR 112017028318A BR 112017028318 A BR112017028318 A BR 112017028318A BR 112017028318 A2 BR112017028318 A2 BR 112017028318A2
Authority
BR
Brazil
Prior art keywords
antibacterial compounds
compounds
tuberculosis
medicaments
integers
Prior art date
Application number
BR112017028318A
Other languages
Portuguese (pt)
Other versions
BR112017028318B1 (en
Inventor
Tahri Abdellah
Émile Georges Guillemont Jérôme
Madeleine Simone Motte Magali
Jean-Marie Bernard Raboisson Pierre
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56289523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017028318(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of BR112017028318A2 publication Critical patent/BR112017028318A2/en
Publication of BR112017028318B1 publication Critical patent/BR112017028318B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

a presente invenção refere-se aos seguintes compostos, em que os números inteiros são como definidos na descrição, e onde os compostos podem ser úteis como medicamentos, por exemplo, para uso no tratamento da tuberculose.The present invention relates to the following compounds, wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for example for use in the treatment of tuberculosis.

BR112017028318-2A 2015-07-02 2016-07-01 ANTIBACTERIAL COMPOUND, ITS USE, PROCESS FOR ITS PREPARATION, PRODUCT CONTAINING IT, PHARMACEUTICAL COMPOSITION AND COMBINATION BR112017028318B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15174936.3 2015-07-02
EP15174936 2015-07-02
EP16174718.3 2016-06-16
EP16174718 2016-06-16
EP16174713 2016-06-16
EP16174713.4 2016-06-16
PCT/EP2016/065499 WO2017001660A1 (en) 2015-07-02 2016-07-01 Antibacterial compounds

Publications (2)

Publication Number Publication Date
BR112017028318A2 true BR112017028318A2 (en) 2018-09-04
BR112017028318B1 BR112017028318B1 (en) 2024-02-20

Family

ID=56289523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028318-2A BR112017028318B1 (en) 2015-07-02 2016-07-01 ANTIBACTERIAL COMPOUND, ITS USE, PROCESS FOR ITS PREPARATION, PRODUCT CONTAINING IT, PHARMACEUTICAL COMPOSITION AND COMBINATION

Country Status (27)

Country Link
US (5) US20180155341A1 (en)
EP (3) EP3316968A1 (en)
JP (3) JP7099824B2 (en)
KR (2) KR20180022833A (en)
CN (3) CN107708809A (en)
AU (3) AU2016287477B2 (en)
BR (1) BR112017028318B1 (en)
CA (2) CA2986326A1 (en)
CL (1) CL2017003404A1 (en)
CO (1) CO2017013408A2 (en)
DK (1) DK3316969T3 (en)
EA (2) EA201890204A1 (en)
ES (1) ES2914681T3 (en)
HK (2) HK1249468A1 (en)
HR (1) HRP20220339T1 (en)
IL (2) IL256391B (en)
LT (1) LT3316969T (en)
MA (1) MA42293A (en)
MD (1) MD3316969T2 (en)
MX (2) MX2017016789A (en)
PE (1) PE20180520A1 (en)
PH (2) PH12017502297A1 (en)
PL (1) PL3316969T3 (en)
RS (1) RS63201B1 (en)
SI (1) SI3316969T1 (en)
UA (1) UA125171C2 (en)
WO (2) WO2017001660A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563017B2 (en) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム Glycosidase inhibitor
NZ737297A (en) 2015-07-02 2024-03-22 Hoffmann La Roche Bicyclic lactams and methods of use thereof
MA42293A (en) * 2015-07-02 2018-05-09 Janssen Sciences Ireland Uc ANTIBACTERIAL COMPOUNDS
AU2016324598A1 (en) 2015-09-17 2018-03-15 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
EA201891438A1 (en) 2016-02-25 2019-01-31 Асенейрон С. А. ACID ADDITIVE SALTS DERIVATIVES OF PIPERAZINE
CN108884078A (en) 2016-02-25 2018-11-23 阿森纽荣股份公司 Glycosidase inhibitor
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
JP7349359B2 (en) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー Bicyclic pyridone lactams and methods of using them.
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3577121A1 (en) * 2017-02-06 2019-12-11 Janssen Pharmaceutica NV Oga inhibitor compounds
EA201991997A1 (en) 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани COMBINED THERAPY
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
TW201920170A (en) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted inhibitors of MENIN-MLL and methods of use
US11149022B2 (en) 2017-10-17 2021-10-19 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
RU2680972C1 (en) * 2018-02-13 2019-03-01 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Method for determining duration of chemotherapy of respiratory tuberculosis with multiple and wide mtb drug resistance in children and teenagers
US20210009583A1 (en) * 2018-03-12 2021-01-14 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN112074519A (en) 2018-04-20 2020-12-11 豪夫迈·罗氏有限公司 N- [ 4-oxo-2, 3-dihydro-1, 5-benzoxazepin-3-yl ] -5, 6-dihydro-4H-pyrrolo [1,2-B ] pyrazole-2-carboxamide derivatives and related compounds as RIP1 kinase inhibitors for the treatment of e.g. Irritable Bowel Syndrome (IBS)
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
CN109503631A (en) * 2018-12-29 2019-03-22 中国医学科学院医药生物技术研究所 Imidazo [1,2-a] pyridine -3- amides compound containing diazaspiracyclic segment and its preparation method and application
US20220235047A1 (en) * 2019-05-28 2022-07-28 Shionogi & Co., Ltd. A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
KR102076958B1 (en) 2019-06-24 2020-02-13 엘티소재주식회사 Hetero-cyclic compound and organic light emitting device using same
TW202124379A (en) 2019-09-10 2021-07-01 日商鹽野義製藥股份有限公司 Benzyl amine-containing 5,6-heteroaromatic compounds useful against mycobacterial infection
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20220389008A1 (en) 2019-09-30 2022-12-08 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
MX2022003816A (en) 2019-09-30 2022-05-06 Janssen Sciences Ireland Unlimited Co Antibacterial compounds.
KR20220122649A (en) 2019-12-27 2022-09-02 테크니메데 소시에다데 테크니코-메디시날 에스.에이. NEW PHARMACEUTICAL COMPOUNDS
EP4308239A1 (en) 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4308579A1 (en) 2021-03-17 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2024509997A (en) 2021-03-17 2024-03-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3223626A1 (en) 2021-06-29 2023-01-05 Augusto Eugenio Pardal Filipe Heterocyclic compounds for the treatment of tuberculosis
TW202325274A (en) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 Antibacterial compounds
WO2023244764A1 (en) * 2022-06-15 2023-12-21 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702733B2 (en) 1994-11-15 1999-03-04 Pharmacia & Upjohn Company Bicyclic oxazine and thiazine oxazolidinone antibacterials
ES2162047T3 (en) 1995-05-11 2001-12-16 Upjohn Co OXAZOLIDINONES WITH REST DIAZINYL AND CARBAZINYL SPIROCICLICAL AND BICYCLE.
ES2395237T3 (en) 2002-07-25 2013-02-11 Janssen Pharmaceutica N.V. Quinoline derivatives as intermediates for mycobacterial inhibitors
AR042956A1 (en) 2003-01-31 2005-07-13 Vertex Pharma GIRASA INHIBITORS AND USES OF THE SAME
MA27360A1 (en) 2004-11-23 2005-06-01 Brahim Bennani SYNTHESIS AND APPLICATION OF SPIRO-ISOXAZOLINES AS ANTI-TUBERCULAR AGENTS
CN101631786A (en) 2006-12-20 2010-01-20 先灵公司 Novel jnk inhibitor
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (en) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd Imidazole carbonyl compounds
JP5613656B2 (en) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント Bicyclic nitroimidazoles covalently linked to substituted phenyloxazolidinones
US8658350B2 (en) 2008-09-22 2014-02-25 Oregon Health & Science University Methods for detecting Mycobacterium tuberculosis disease
US20120040951A1 (en) 2008-12-30 2012-02-16 Claudio Chuaqui Heteroaryl compounds useful as raf kinase inhibitors
BR112012010752B1 (en) 2009-11-05 2021-07-20 University Of Notre Dame Du Lac IMIDAZO[1,2-A]PYRIDINE COMPOUNDS
SG184073A1 (en) * 2010-03-18 2012-10-30 Pasteur Institut Korea Anti-infective compounds
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
CA2845785A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013127269A1 (en) * 2012-03-02 2013-09-06 Genentech,Inc. Amido spirocyclic amide and sulfonamide derivatives
KR101918469B1 (en) 2012-06-04 2018-11-15 한국화학연구원 Bicyclic nitroimidazole derivatives or their optical isomers, pharmaceutical composition containing the same as an active ingredient
JP6483610B2 (en) * 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック 5,5-heteroaromatic anti-infective compound
KR101650716B1 (en) 2012-11-22 2016-08-24 한국화학연구원 Bicyclic nitroimidazole derivatives, preparation method thereof and pharmaceutical composition for prevention or treatment of tuberculosis containing the same as an active ingredient
ES2883565T3 (en) * 2013-08-02 2021-12-09 Pasteur Institut Korea Anti-infective compounds
KR101564425B1 (en) 2013-11-26 2015-10-30 한국화학연구원 Novel bicyclic nitroimidazole carbamate compounds, process for preparation thereof and pharmaceutical composition for preventing or treating tuberculosis containing the same as an active ingredient
CN105524058B (en) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 Pyrazolo [1,5 a] pyridine compounds and their and its application
EP3215225B1 (en) 2014-11-03 2020-01-08 The Regents of the University of California Multi-drug therapies for tuberculosis treatment
MA42293A (en) * 2015-07-02 2018-05-09 Janssen Sciences Ireland Uc ANTIBACTERIAL COMPOUNDS
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
CA3025727A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EA201991997A1 (en) 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани COMBINED THERAPY

Also Published As

Publication number Publication date
WO2017001660A1 (en) 2017-01-05
AU2016287477A1 (en) 2017-11-30
CN108235704A (en) 2018-06-29
DK3316969T3 (en) 2022-05-02
EP4074378A1 (en) 2022-10-19
WO2017001661A1 (en) 2017-01-05
KR20180022826A (en) 2018-03-06
PE20180520A1 (en) 2018-03-14
BR112017028318B1 (en) 2024-02-20
LT3316969T (en) 2022-03-25
AU2022200385A1 (en) 2022-02-17
AU2016287477B2 (en) 2021-10-21
PH12017502297A1 (en) 2018-06-25
CA2986326A1 (en) 2017-01-05
EA201890201A1 (en) 2018-06-29
JP2018524339A (en) 2018-08-30
ES2914681T3 (en) 2022-06-15
PH12017502298A1 (en) 2018-06-11
CN113980015A (en) 2022-01-28
JP2018519302A (en) 2018-07-19
MX2017016788A (en) 2018-07-06
US11866419B2 (en) 2024-01-09
JP7099824B2 (en) 2022-07-12
IL256391A (en) 2018-02-28
HK1254677A1 (en) 2019-07-26
MD3316969T2 (en) 2022-07-31
EP3316969A1 (en) 2018-05-09
US20230014173A1 (en) 2023-01-19
EP3316969B1 (en) 2022-03-02
US20180186768A1 (en) 2018-07-05
US20190330189A1 (en) 2019-10-31
MA42293A (en) 2018-05-09
PL3316969T3 (en) 2022-06-20
US20200239434A1 (en) 2020-07-30
US11180472B2 (en) 2021-11-23
UA125171C2 (en) 2022-01-26
HK1249468A1 (en) 2018-11-02
HRP20220339T1 (en) 2022-05-13
JP2022043078A (en) 2022-03-15
IL256391B (en) 2021-03-25
PH12017502298B1 (en) 2018-06-11
MX2017016789A (en) 2018-06-11
IL256379A (en) 2018-02-28
CA2986331A1 (en) 2017-01-05
EA201890204A1 (en) 2018-06-29
SI3316969T1 (en) 2022-05-31
US10364232B2 (en) 2019-07-30
AU2016287478B2 (en) 2021-10-21
RS63201B1 (en) 2022-06-30
AU2016287478A1 (en) 2017-11-30
CL2017003404A1 (en) 2018-05-11
EP3316968A1 (en) 2018-05-09
CN108235704B (en) 2021-10-26
US20180155341A1 (en) 2018-06-07
KR20180022833A (en) 2018-03-06
CN107708809A (en) 2018-02-16
CO2017013408A2 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112017028318A2 (en) antibacterial compounds
BR112018076126A2 (en) heterocyclic compounds as antibacterials
BR112018075939A2 (en) heterocyclic compounds as antibacterials
CL2016000839A1 (en) Compositions to modulate the expression of c9orf72.
BR112017007636A2 (en) methods for preparing ribosides
BR112017007123A2 (en) tetrahydroisoquinoline derivatives
CR20170478A (en) NEW COMPOUNDS
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CL2015002891A1 (en) Deaza-macrocyclic purinones for the treatment of viral infections.
CR20150326A (en) AUTOTAXIN INHIBITORS
BR112022003799A2 (en) antibacterial compounds
BR112018008441A2 (en) polypropylene composition, use of a polypropylene composition, layer element, article, and photovoltaic module.
BR112017013498A2 (en) nitrification inhibitor compositions and methods for preparing them
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
BR112017000821A2 (en) new substituted pyrimidine compounds.
UY37193A (en) NEW ANTIVÍRICOS COMPOUNDS
GT201600066A (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1
CL2016000038A1 (en) Pyroxolo-substituted pyridinamines
BR112017008496A2 (en) compounds for use in anthelmintic treatment
BR112017019750A2 (en) process for preparing a crystalline form of menaquinol, crystalline form of menaquinol, process for preparing a solid form of menaquinol, pharmaceutical or nutraceutical composition and use of the crystalline form of menaquinol
UY36217A (en) PIRIDONA SUBSTITUTE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
BR112017005272A2 (en) cysteamine to treat yeast / mold infections
UY36292A (en) TETRAHYDROQUINOLINE COMPOUNDS FOR USE AS BROMODOMINIUM INHIBITORS
DOP2018000049A (en) COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
BR112016013946A8 (en) quinazolin-thf-amines as pde1 inhibitors, pharmaceutical composition comprising them, process for preparing said pharmaceutical composition as well as use of the compounds and kit

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/2016, OBSERVADAS AS CONDICOES LEGAIS